BEIJING (Reuters) – Sinopharm unit China National Medicines on Friday said it does not have any business dealings or relations with Shanxi Osteorad Biomaterial Co, according to a filing to the Shanghai Stock Exchange.
Shanxi Osteorad is suspected of illegally purchasing human remains and limbs to be used as raw materials for the production of “allogeneic bone implantable materials”, government-backed media The Paper reported previously.
(Reporting by Beijing newsroom; Editing by Tom Hogue)
Comments